Evolution of immune evasion and host range expansion by the SARS-CoV-2 B. 1.1. 529 (Omicron) variant
W Ren, Y Zhang, J Rao, Z Wang, J Lan, K Liu, X Zhang… - MBio, 2023 - Am Soc Microbiol
Recently, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant B. 1.1.
529 (Omicron) has rapidly become the dominant strain, with an unprecedented number of …
529 (Omicron) has rapidly become the dominant strain, with an unprecedented number of …
Need of booster vaccine doses to counteract the emergence of SARS-CoV-2 variants in the context of the Omicron variant and increasing COVID-19 cases: An update
The emergence of different variants of SARS-CoV-2, including the Omicron (B. 1.1. 529)
variant in November 2021, has resulted in a continuous major health concern at a global …
variant in November 2021, has resulted in a continuous major health concern at a global …
COVID-19 vaccination and rates of infections, hospitalizations, ICU admissions, and deaths in the European Economic Area during autumn 2021 wave of SARS-CoV …
The COVID-19 vaccination campaigns were met with a varying level of vaccine hesitancy in
Europe. We analyzed the potential relationships between COVID-19 vaccine coverage in …
Europe. We analyzed the potential relationships between COVID-19 vaccine coverage in …
Individuals with weaker antibody responses after booster immunization are prone to omicron breakthrough infections
B Möhlendick, I Čiučiulkaitė, C Elsner… - Frontiers in …, 2022 - frontiersin.org
Background Despite the high level of protection against severe COVID-19 provided by the
currently available vaccines some breakthrough infections occur. Until now, there is no …
currently available vaccines some breakthrough infections occur. Until now, there is no …
Functional properties of the spike glycoprotein of the emerging SARS-CoV-2 variant B. 1.1. 529
Summary The recently emerged B. 1.1. 529 (Omicron) severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) variant has a highly divergent spike (S) glycoprotein. We …
coronavirus 2 (SARS-CoV-2) variant has a highly divergent spike (S) glycoprotein. We …
Long-term safety and effectiveness of mRNA-1273 vaccine in adults: COVE trial open-label and booster phases
LR Baden, HM El Sahly, B Essink, D Follmann… - Nature …, 2024 - nature.com
Abstract Primary vaccination with mRNA-1273 (100-µg) was safe and efficacious at
preventing coronavirus disease 2019 (COVID-19) in the previously reported, blinded Part A …
preventing coronavirus disease 2019 (COVID-19) in the previously reported, blinded Part A …
COVID-19 vaccines against Omicron variant: real-world data on effectiveness
Y Kherabi, O Launay, LB Luong Nguyen - Viruses, 2022 - mdpi.com
The efficacy of vaccines against coronavirus disease 2019 (COVID-19) has now been well
established in phase III clinical trials. However, clinical studies based on real-world data …
established in phase III clinical trials. However, clinical studies based on real-world data …
Immunogenicity and reactogenicity against the SARS-CoV-2 variants following heterologous primary series involving CoronaVac, ChAdox1 nCov-19 and BNT162b2 …
S Niyomnaitham, Z Quan Toh… - Human Vaccines & …, 2022 - Taylor & Francis
We evaluated the immunogenicity and reactogenicity of heterologous COVID-19 primary
schedules involving BNT162b2 (Pfizer-BioNTech), ChAdOx1 nCoV-19 (AstraZeneca) and …
schedules involving BNT162b2 (Pfizer-BioNTech), ChAdOx1 nCoV-19 (AstraZeneca) and …
Effectiveness of COVID-19 vaccines against SARS-CoV-2 Omicron variant (B. 1.1. 529): a systematic review with meta-analysis and meta-regression
Vaccine effectiveness (VE) and the urgency of booster vaccination against SARS-CoV-2
Omicron variant need evaluation. A systematic search was conducted from 1–6 April, 2022 …
Omicron variant need evaluation. A systematic search was conducted from 1–6 April, 2022 …
Primary exposure to SARS-CoV-2 via infection or vaccination determines mucosal antibody-dependent ACE2 binding inhibition
J Fröberg, VJCH Koomen… - The Journal of …, 2024 - academic.oup.com
Background Mucosal antibodies play a critical role in preventing SARS-CoV-2 infections or
reinfections by blocking the interaction of the receptor-binding domain (RBD) with the …
reinfections by blocking the interaction of the receptor-binding domain (RBD) with the …